Fractalkine (FKN) has been implicated in modulation of angiogenesis and vascular inflammation, but the underlying mechanism has not been elucidated. We have investigated the molecular mechanism by which FKN regulates angiogenesis. We found that recombinant FKN increases in vitro proliferation, migration, and tube formation of human umbilical vein endothelial cells and stimulates in vivo angiogenesis. FKN-induced angiogenesis was accompanied by phosphorylation of ERK, Akt, and endothelial nitric oxide (NO) synthase (eNOS), as well as an increase in NO production. These biochemical events and angiogenesis were completely inhibited by the G protein-coupled receptor inhibitor pertussis toxin. Inhibitors of Raf-1, MEK, phosphatidylinositol 3-kinase (PI3K), and eNOS or transfection with dominant-negative forms of ERK and Akt significantly suppressed the angiogenic activity of FKN. However, inhibitors of Raf-1 and MEK or a dominant-negative ERK mutant blocked FKN-induced ERK, but not Akt and eNOS, phosphorylation. The PI3K inhibitor and a dominant-negative mutant of Akt suppressed Akt and eNOS phosphorylation and NO production. Our results demonstrated that FKN stimulated angiogenesis by activating the Raf-1/MEK/ERK and PI3K/Akt/eNOS/NO signal pathways via the G protein-coupled receptor CX3CR1, indicating that two pathways are required for full angiogenic activity of FKN. This study suggests that FKN may play an important role in the pathophysiological process of inflammatory angiogenesis.
Abstract-Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) are potent angiogenic factors that have been used clinically to induce angiogenesis. However, concerns have been raised about VEGF because of its proinflammatory actions, which include enhancing the adhesion of leukocytes to endothelial cells. We have examined the possible antiinflammatory effects of HGF on the vasculature. HGF, unlike VEGF, did not alter leukocyte adhesion to endothelial cells. Instead it inhibited VEGF-induced leukocyte-endothelial cell interactions and the endothelial expression of intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). In a skin inflammation model, VEGF-treated mice showed a significant increase of leukocytes infiltrated or adherent to the luminal surface of blood vessels, as compared with vehicle-or HGF-treated mice. The VEGF effect was markedly suppressed by coadministration of HGF. RT-PCR and promoter analysis revealed that HGF downregulated VEGFmediated expression of ICAM-1 and VCAM-1 at the transcriptional level. Furthermore, these inhibitory effects coincided with suppression of IB kinase activity, and this in turn prevented the activation of the inflammatory transcription factor NF-B. Taken together, our results demonstrate that HGF suppresses VEGF-induced inflammation presumably by inhibiting the endothelial NF-B pathway. This suggests that combined treatment with HGF and VEGF could be superior to treatment with either factor alone for enhancing therapeutic angiogenesis while avoiding inflammation. (Circ Res. 2005;96:300-307.)
IntroductionAngiogenesis, the formation of new blood vessels from a preexisting vascular bed, is a pivotal process not only in embryonic development but also in the progression of a variety of pathologic conditions. 1 A large number of molecules, which are composed of growth factors, cytokines, and lipid metabolites, are shown to be involved in pathophysiologic neovascularization by stimulating endothelial cells (ECs) directly or indirectly. 2 Some of these factors, including VEGF, often possess their abilities to increase vascular permeability and thus contribute to deteriorating tissue damage.Receptor activator of nuclear factor (NF)-B ligand (RANKL), also known as ODF, TRANCE, and OPGL, has well-understood roles in the skeletal and immune systems in which it induces osteoclast differentiation from hematopoietic precursors and regulates the function and survival of dendritic cells. 3 Recently, interest has grown in its physiologic and pathologic relevance to vascular biology. 4 Mounting evidence suggests that RANKL and its decoy receptor, osteoprotegrin (OPG), participate in multiple aspects of vascular calcification; for example, mice lacking OPG suffer late medial calcification of the renal and aortic arteries in addition to early onset osteoporosis. [5][6][7] Moreover, a role for the OPG/RANKL/ RANK axis in atherogenesis and plaque destabilization has been recently reported. 8 OPG inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE Ϫ/Ϫ mice. 9 TRANCE is strongly expressed in vascular cells in vitro, as well as in vivo. OPG and it are induced by inflammatory cytokines in human ECs, although with different temporal profiles. 10 In vivo, RANKL is present in the small blood vessels of the skin and in arterial smooth muscle cells, 11 and it appears to be up-regulated in atherosclerotic lesions, calcified vessels, and valves. 4,6,9 Moreover, the RANKL receptor, RANK, is also expressed in ECs of the rat coronary artery and developing blood vessels of the rat embryo in vivo, as well as in freshly isolated human umbilical vein ECs (HUVECs). 12 In agreement with these patterns of expression, RANKL stimulates the survival of cultured ECs and their production of inflammatory cell adhesion molecules; it also promotes in vitro angiogenesis by the ECs and elicits neoangiogenesis in animal models. 13 Moreover, VEGF increases RANK mRNA and protein in ECs, augmenting their angiogenic response to RANKL. 12 Therefore, the RANKL/RANK/OPG system is believed to be an important link between the vascular, skeletal, and immune systems.Endothelium-derived nitric oxide (NO), originally identified as endothelium-derived relaxing factor, promotes angiogenesis and plays an important role in vascular remodeling and the maintenance of vascular integrity. 14,15 In ECs, NO is a product of the An Inside Blood analysis of this article appears at the front of this issue.The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact,...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.